Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06638710 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Oral Midazolam Used for the Delivery of Care in Elderly Patient With Neurocognitive Disorders and Refusing Care.

Study acronym: MIRAGE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 15, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 31, 2025 to Jul 8, 2025
    • Site details revised
    v4
  2. Start date: Jan 1, 2025 to May 31, 2025v3
  3. Start date: Nov 1, 2024 to Jan 1, 2025v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the effectiveness of oral midazolam on the delivery of care in elderly patients with moderat to severe neurocognitive disorders and opposing care.
Trial Details
NCT Number NCT06638710
Lead Sponsor University Hospital, Grenoble
Conditions
(from sponsor)		 Neurocognitive Disorders
Related terms Neurocognitive Disorders
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov